Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

Abstract Venetoclax is approved as monotherapy and in combination with rituximab for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Two Phase 1 studies (M12‐175 [NCT01328626]; M13‐365 [NCT01682616]) were conducted in which patients who initially responded and then progressed on veneto...

Full description

Bibliographic Details
Main Authors: Sasanka Handunnetti, Mary Ann Anderson, Andrew W. Roberts, Matthew S. Davids, Shuo Ma, Michelle Boyer, Jennifer Arzt, Abdullah Al Masud, Relja Popovic, Amanda Jacobson, Su Y. Kim, John F. Seymour
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:eJHaem
Subjects:
chronic lymphocytic leukemia
relapsed/refractory
rituximab
small lymphocytic lymphoma
venetoclax
Online Access:https://doi.org/10.1002/jha2.177

Internet

https://doi.org/10.1002/jha2.177

Similar Items